

# Albert J Czaja

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4800950/albert-j-czaja-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

280  
papers

20,926  
citations

78  
h-index

135  
g-index

300  
ext. papers

23,801  
ext. citations

6.1  
avg, IF

7.37  
L-index

#	Paper	IF	Citations
280	International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 929-38	13.4	2240
279	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 169-76	11.2	1166
278	Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , <b>2010</b> , 51, 2193-213	11.2	979
277	Diagnosis and treatment of autoimmune hepatitis. <i>Hepatology</i> , <b>2002</b> , 36, 479-97	11.2	406
276	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 2816-2835	8.7	275
275	Frequency and nature of the variant syndromes of autoimmune liver disease. <i>Hepatology</i> , <b>1998</b> , 28, 360-5	11.2	272
274	Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1824-32	13.3	253
273	Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1996</b> , 110, 848-57	13.3	239
272	Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1997</b> , 25, 317-23	11.2	227
271	Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1997</b> , 112, 2028-35	13.3	216
270	Host- and disease-specific factors affecting steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>1998</b> , 29, 198-206	13.4	215
269	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 2515-32	5.6	213
268	Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. <i>Gastroenterology</i> , <b>2010</b> , 139, 58-72.e4	13.3	211
267	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>2000</b> , 31, 49-53	11.2	198
266	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2020</b> , 72, 671-722	11.2	198
265	Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 646-52	13.4	187
264	Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. <i>Gastroenterology</i> , <b>1992</b> , 103, 1290-5	13.3	179

263	Drug-induced autoimmune-like hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 958-76	4	178
262	Significance of HLA DR4 in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1502-7	13.3	168
261	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1996</b> , 24, 1068-73	11.2	163
260	Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. <i>Immunological Reviews</i> , <b>2000</b> , 174, 250-9	11.3	160
259	The variant forms of autoimmune hepatitis. <i>Annals of Internal Medicine</i> , <b>1996</b> , 125, 588-98	8	158
258	Recurrent autoimmune hepatitis after orthotopic liver transplantation. <i>Liver Transplantation</i> , <b>2001</b> , 7, 302-10	4.5	156
257	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Hepatology</i> , <b>1992</b> , 15, 215-21	11.2	153
256	Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 394-401	13.4	149
255	Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>1999</b> , 30, 851-6	11.2	148
254	Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. <i>Hepatology</i> , <b>2006</b> , 43, 532-8	11.2	146
253	High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1995</b> , 108, 1159-66	13.3	144
252	Autoimmune hepatitis with incidental histologic features of bile duct injury. <i>Hepatology</i> , <b>2001</b> , 34, 659-65	11.2	143
251	Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , <b>1984</b> , 4, 622-7	11.2	142
250	Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. <i>Gastroenterology</i> , <b>1999</b> , 117, 645-52	13.3	141
249	Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 1903-9	4	141
248	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18017	51.1	140
247	Autoimmune hepatitis. Evolving concepts and treatment strategies. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 435-56	4	138
246	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , <b>1983</b> , 85, 713-717	13.3	138

245	Natural history, clinical features, and treatment of autoimmune hepatitis. <i>Seminars in Liver Disease</i> , <b>1984</b> , 4, 1-12	7.3	138
244	The nature and prognostic implications of autoimmune hepatitis with an acute presentation. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 866-71	13.4	135
243	Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 1540-8	11.2	132
242	The validity and importance of subtypes in autoimmune hepatitis: a point of view. <i>American Journal of Gastroenterology</i> , <b>1995</b> , 90, 1206-11	0.7	130
241	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 2190-5	4	128
240	Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1992</b> , 14, 325-31	13.4	126
239	Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1005-12	0.7	125
238	Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 105, 1522-8	13.3	123
237	Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. <i>Hepatology</i> , <b>2002</b> , 35, 890-7	11.2	120
236	Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. <i>Gut</i> , <b>2002</b> , 51, 259-64	19.2	119
235	Autoantibodies in liver disease. <i>Gastroenterology</i> , <b>2001</b> , 120, 239-49	13.3	117
234	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 413-9	0.7	116
233	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , <b>1981</b> , 80, 687-692	13.3	115
232	Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. <i>New England Journal of Medicine</i> , <b>1981</b> , 304, 5-9	59.2	115
231	Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. <i>Hepatology</i> , <b>2007</b> , 46, 1138-45	11.2	113
230	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. <i>Hepatology</i> , <b>1999</b> , 30, 1381-6	11.2	112
229	Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 121, 364-74	6.2	111
228	Immunologic features and HLA associations in chronic viral hepatitis. <i>Gastroenterology</i> , <b>1995</b> , 108, 157-64	3.3	111

227	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , <b>1980</b> , 78, 518-523	13.3	111
226	Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2051-7	0.7	108
225	The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. <i>Hepatology</i> , <b>1989</b> , 9, 193-7	11.2	108
224	Validation of scoring system for diagnosis of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 305-14	4	106
223	Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. <i>Gastroenterology</i> , <b>1994</b> , 107, 200-7	13.3	106
222	Genetic predispositions for the immunological features of chronic active hepatitis. <i>Hepatology</i> , <b>1993</b> , 18, 816-22	11.2	105
221	Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. <i>Gastroenterology</i> , <b>2000</b> , 119, 1312-6	13.3	104
220	Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , <b>1988</b> , 95, 448-53	13.3	104
219	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 436-42	15.5	103
218	Autoimmune cholangitis within the spectrum of autoimmune liver disease. <i>Hepatology</i> , <b>2000</b> , 31, 1231-8	11.2	100
217	Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1986</b> , 31, 705-11	4	98
216	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. <i>Liver</i> , <b>1984</b> , 4, 105-16		97
215	Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. <i>Hepatology</i> , <b>2004</b> , 39, 1631-8	11.2	97
214	Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 302-8	13.4	94
213	The nature and prognosis of severe cryptogenic chronic active hepatitis. <i>Gastroenterology</i> , <b>1993</b> , 104, 1755-61	13.3	93
212	Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. <i>American Journal of Surgical Pathology</i> , <b>1995</b> , 19, 699-708	6.7	93
211	Understanding the pathogenesis of autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1224-31	0.7	92
210	Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 52-9	13.4	91

209	Acute and acute severe (fulminant) autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 897-914	90
208	Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. <i>Journal of Hepatology</i> , <b>1993</b> , 18, 342-52	13.4 87
207	Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 161-7	13.4 85
206	Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1987</b> , 92, 215-9	13.3 84
205	Safety issues in the management of autoimmune hepatitis. <i>Expert Opinion on Drug Safety</i> , <b>2008</b> , 7, 319-341	83
204	Consequences of treatment withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2007</b> , 27, 507-15	7.9 81
203	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. <i>Gut and Liver</i> , <b>2016</b> , 10, 177-203	4.8 81
202	Histological findings in chronic hepatitis C with autoimmune features. <i>Hepatology</i> , <b>1997</b> , 26, 459-66	11.2 76
201	Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. <i>Liver Transplantation</i> , <b>2002</b> , 8, 505-13	4.5 76
200	The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 685-705	4.6 76
199	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. <i>Hepatology</i> , <b>1997</b> , 26, 567-72	11.2 75
198	Genetic bases of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2002</b> , 47, 2139-50	4 75
197	TrueSantimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. <i>Clinical and Experimental Immunology</i> , <b>2004</b> , 135, 154-8	6.2 74
196	Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. <i>Journal of Clinical Gastroenterology</i> , <b>2005</b> , 39, 819-25	3 74
195	Treatment of autoimmune hepatitis. <i>Seminars in Liver Disease</i> , <b>2002</b> , 22, 365-78	7.3 74
194	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1984</b> , 87, 1222-1227	13.3 74
193	Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 379-88	6.9 73
192	Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. <i>The American Journal of Digestive Diseases</i> , <b>1977</b> , 22, 973-80	73

191	Treatment challenges and investigational opportunities in autoimmune hepatitis. <i>Hepatology</i> , <b>2005</b> , 41, 207-15	11.2	71
190	Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 2248-66	4	70
189	Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1944-51	0.7	68
188	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. <i>Liver International</i> , <b>2004</b> , 24, 322-9	7.9	67
187	Autoimmune hepatitis and its variant syndromes. <i>Gut</i> , <b>2001</b> , 49, 589-94	19.2	67
186	Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1997</b> , 42, 1688-96	4	66
185	Hepatocellular carcinoma in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 1944-8	4	65
184	Autoimmune hepatitis: the investigational and clinical challenges. <i>Hepatology</i> , <b>2000</b> , 31, 1194-200	11.2	64
183	Autoantibodies as prognostic markers in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2144-61	4	63
182	Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Hepatology</i> , <b>1988</b> , 8, 1679-83	11.2	63
181	Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2003</b> , 23, 116-23	7.9	61
180	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , <b>2007</b> , 69, 227-35		60
179	Autoimmune hepatitis. Part A: pathogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2007</b> , 1, 113-28	4.2	60
178	Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , <b>1990</b> , 11, 1044-9	11.2	59
177	Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 1733-40	4	57
176	Autoantibody-negative autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 610-24	4	56
175	Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 968-75	4	56
174	Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2012</b> , 32, 85-92	7.9	54

173	Difficult treatment decisions in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 934-43	4.7	54
172	Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Hepatology</i> , <b>1989</b> , 10, 39-43	11.2	54
171	The overlap syndromes of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 326-43	4	53
170	Drug therapy in the management of type 1 autoimmune hepatitis. <i>Drugs</i> , <b>1999</b> , 57, 49-68	12.1	53
169	Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. <i>Gastroenterology</i> , <b>1990</b> , 98, 1587-93	13.3	53
168	Features and consequences of untreated type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2009</b> , 29, 816-23	7.9	52
167	Immune phenotype of chronic liver disease. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 2149-55	4	52
166	Genetic distinctions between types 1 and 2 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 2197-200	0.7	52
165	Performance parameters of the conventional serological markers for autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 545-54	4	51
164	Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 385-406	6.1	50
163	Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 261-79	6.1	50
162	Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 691-707	6.1	50
161	Autoantibodies in the diagnosis and management of liver disease. <i>Journal of Clinical Gastroenterology</i> , <b>2003</b> , 37, 315-29	3	49
160	Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. <i>Autoimmunity</i> , <b>2002</b> , 35, 475-83	3	49
159	Chronic active hepatitis: the challenge for a new nomenclature. <i>Annals of Internal Medicine</i> , <b>1993</b> , 119, 510-7	8	49
158	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 6-24	3.1	48
157	Shared genetic risk factors in autoimmune liver disease. <i>Digestive Diseases and Sciences</i> , <b>2001</b> , 46, 140-7	4	48
156	Frequency and significance of antibodies to histones in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 32-8	13.4	48



155	Nonstandard antibodies as prognostic markers in autoimmune hepatitis. <i>Autoimmunity</i> , <b>2004</b> , 37, 195-203		47
154	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 343-64	6.1	45
153	Diagnosis and management of the overlap syndromes of autoimmune hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 417-23		45
152	Current and future treatments of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2009</b> , 3, 269-91	4.2	45
151	Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42, 1047-53	3	45
150	Autoimmune hepatitis in diverse ethnic populations and geographical regions. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2013</b> , 7, 365-85	4.2	44
149	Treatment strategies in autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 799-824	4.6	44
148	Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1990</b> , 65, 23-30	6.4	44
147	Cholestatic phenotypes of autoimmune hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1430-8	6.9	41
146	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 859-868	5.6	40
145	Advances in the current treatment of autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1996-2010	4	40
144	Optimizing diagnosis from the medical liver biopsy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 898-907	6.9	40
143	Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2277-2292	4	39
142	Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. <i>Seminars in Liver Disease</i> , <b>2009</b> , 29, 315-30	7.3	39
141	Diagnosis and therapy of autoimmune liver disease. <i>Medical Clinics of North America</i> , <b>1996</b> , 80, 973-94	7	39
140	Autoantibodies in autoimmune liver disease. <i>Advances in Clinical Chemistry</i> , <b>2005</b> , 40, 127-64	5.8	38
139	Diagnosis and management of autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2015</b> , 19, 57-79	4.6	37
138	Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. <i>Gastroenterology</i> , <b>2011</b> , 140, 1472-80	13.3	37

137	Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 1028-35	4	37
136	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , <b>1979</b> , 77, 629-633	13.3	37
135	Recurrent and De Novo Autoimmune Hepatitis. <i>Liver Transplantation</i> , <b>2019</b> , 25, 152-166	4.5	37
134	Cryptogenic chronic hepatitis and its changing guise in adults. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 3421-38	4	36
133	Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 1459-76	4	35
132	Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 2881-900	4	35
131	Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 707-25	4.6	35
130	Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. <i>Drugs and Aging</i> , <b>2008</b> , 25, 219-39	4.7	34
129	Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 251-2	13.4	34
128	Extrahepatic immunologic features of chronic viral hepatitis. <i>Digestive Diseases</i> , <b>1997</b> , 15, 125-44	3.2	33
127	Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1998</b> , 13, 483-9	4	33
126	Frequency and significance of antibodies to chromatin in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 1658-64	4	33
125	Targeting apoptosis in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2014</b> , 59, 2890-904	4	32
124	Current therapy for autoimmune hepatitis. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2007</b> , 4, 202-14		32
123	Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 1237-52	6.4	32
122	Variant forms of autoimmune hepatitis. <i>Current Gastroenterology Reports</i> , <b>1999</b> , 1, 63-70	5	32
121	Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1991</b> , 66, 572-82	6.4	32
120	Autoimmune hepatitis: focusing on treatments other than steroids. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 615-20		31

119	Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3120-40	3.3	31
118	Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 33-40	4	31
117	Autoimmune hepatitis in special patient populations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 689-700	2.5	30
116	Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2314-28	5.6	30
115	Drug choices in autoimmune hepatitis: part B--Nonsteroids. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2012</b> , 6, 617-35	4.2	29
114	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 173-182	6.1	29
113	Drug choices in autoimmune hepatitis: part A--Steroids. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2012</b> , 6, 603-15	4.2	28
112	Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 1322-31	4	28
111	Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. <i>Mayo Clinic Proceedings</i> , <b>1980</b> , 55, 360-4	6.4	28
110	Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. <i>Gastroenterology</i> , <b>1983</b> , 85, 713-7	13.3	27
109	Cell mediators of autoimmune hepatitis and their therapeutic implications. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 1528-42	4	26
108	Current and prospective pharmacotherapy for autoimmune hepatitis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1715-36	4	26
107	Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. <i>Liver International</i> , <b>2006</b> , 26, 552-8	7.9	26
106	Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 2098-106	4	26
105	Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis. <i>Hepatology</i> , <b>1986</b> , 6, 976-80	11.2	26
104	Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. <i>Gastroenterology</i> , <b>1981</b> , 80, 687-92	13.3	26
103	Diverse manifestations and evolving treatments of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2005</b> , 51, 313-33	1.6	26
102	Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. <i>Liver International</i> , <b>2006</b> , 26, 1201-8	7.9	25

101	Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. <i>Journal of Hepatology</i> , <b>1992</b> , 14, 88-93	13.4	25
100	Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. <i>Gastroenterology</i> , <b>1989</b> , 97, 1288-93	13.3	25
99	Auto-immune chronic active hepatitis: a specific entity? The negative argument. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1990</b> , 5, 343-51	4	25
98	Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1982</b> , 57, 303-9	6.4	25
97	Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2712-26	4	24
96	Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1761-9	4	23
95	Autoimmune hepatitis. Part B: diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2007</b> , 1, 129-43	4.2	23
94	Celiac disease-associated autoimmune cholangitis. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 3196-87	6.7	23
93	Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 324-344	4	23
92	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 3118-3139	4.9	22
91	Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1043-58	6.1	22
90	Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. <i>Gastroenterology</i> , <b>1980</b> , 78, 518-23	13.3	22
89	Epigenetic changes and their implications in autoimmune hepatitis. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12899	4.6	21
88	Animal models of autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2010</b> , 4, 429-43	4.2	20
87	Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 179-84	4	20
86	Autoantibodies. <i>Baillieres Clinical Gastroenterology</i> , <b>1995</b> , 9, 723-44		20
85	Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 920-937	6.1	19
84	How lupoid is lupoid hepatitis?. <i>Journal of Rheumatology</i> , <b>1986</b> , 13, 95-8	4.1	19

83	Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 681-701	6.1	19
82	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2009</b> , 25, 215-22	3	18
81	Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. <i>Journal of Hepatology</i> , <b>1993</b> , 17, 180-6	13.4	18
80	Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 2784-2803	4	17
79	Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. <i>Liver International</i> , <b>2005</b> , 25, 410-9	7.9	17
78	Viral Genotypes as Determinants of Autoimmune Expression in Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , <b>1999</b> , 74, 454-460	6.4	17
77	Current problems in the diagnosis and management of chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1981</b> , 56, 311-23	6.4	17
76	Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 1725-31	4	16
75	HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 522-8	4	16
74	Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. <i>Gastroenterology</i> , <b>1992</b> , 102, 1675-9	13.3	16
73	Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1987</b> , 93, 687-92	13.3	16
72	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , <b>2020</b> , 72, 753-769	11.2	15
71	Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. <i>Inflammation and Allergy: Drug Targets</i> , <b>2012</b> , 11, 337-50		15
70	Frequency and significance of antibodies to <i>Saccharomyces cerevisiae</i> in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2004</b> , 49, 611-8	4	15
69	Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1990</b> , 65, 1303-13	6.4	15
68	Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. <i>Gastroenterology</i> , <b>1984</b> , 87, 1222-7	13.3	15
67	Challenges in the diagnosis and management of autoimmune hepatitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 531-9		14
66	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2008</b> , 24, 298-305	3	14

65	Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. <i>Autoimmunity</i> , <b>2006</b> , 39, 341-8	3	14
64	Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II. <i>Inflammation and Allergy: Drug Targets</i> , <b>2012</b> , 11, 351-63		13
63	The role of autoantibodies as diagnostic markers of autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , <b>2006</b> , 2, 33-48	5.1	13
62	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2007</b> , 23, 255-62	3	13
61	Autoimmune hepatitis and viral infection. <i>Gastroenterology Clinics of North America</i> , <b>1994</b> , 23, 547-66	4.4	13
60	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 6579-6606	5.6	13
59	Current concepts in autoimmune hepatitis. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 6-24	3.1	13
58	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 345-364	4.4	12
57	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2006</b> , 22, 234-40	3	12
56	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1706-1725	4	11
55	Autoimmune liver disease and rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , <b>2007</b> , 19, 74-80	5.3	11
54	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2003</b> , 19, 232-42	3	11
53	Systemic mycosis complicating high dose corticosteroid treatment of chronic active liver disease. <i>American Journal of Gastroenterology</i> , <b>1980</b> , 74, 428-32	0.7	11
52	Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2007</b> , 53, 43-78	1.6	11
51	Evolving paradigm of treatment for autoimmune hepatitis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 781-798	5.1	10
50	Adoptive cell transfer in autoimmune hepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 821-36	4.2	10
49	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 547-564	4.2	10
48	Malignancy in Chronic Liver Disease. <i>Gastroenterology</i> , <b>1977</b> , 73, 192-193	13.3	10

47	Autoimmune hepatitis--approach to diagnosis. <i>MedGenMed: Medscape General Medicine</i> , <b>2006</b> , 8, 55		10
46	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , <b>2019</b> , 52, 144-160	3	9
45	Overlap syndromes. <i>Clinical Liver Disease</i> , <b>2014</b> , 3, 2-5	2.2	9
44	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2004</b> , 20, 231-40	3	9
43	Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. <i>Gastroenterology</i> , <b>1979</b> , 77, 629-33	13.3	8
42	Emerging treatments for autoimmune hepatitis. <i>Inflammation and Allergy: Drug Targets</i> , <b>2002</b> , 1, 317-26		7
41	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2005</b> , 21, 293-9	3	6
40	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2002</b> , 18, 334-44	3	6
39	Progress in the diagnosis and treatment of autoimmune hepatitis. <i>Minerva Medica</i> , <b>2008</b> , 99, 549-68	2.2	6
38	GB virus-C infection in type 1 autoimmune hepatitis.. <i>Mayo Clinic Proceedings</i> , <b>1998</b> , 73, 412-418	6.4	5
37	Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis <b>1997</b> , 26, 567		5
36	Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1286-1304	6.1	4
35	Management of Recalcitrant Autoimmune Hepatitis. <i>Current Hepatitis Reports</i> , <b>2013</b> , 12, 66-77		4
34	GB virus-C infection in type 1 autoimmune hepatitis. <i>Mayo Clinic Proceedings</i> , <b>1998</b> , 73, 412-8	6.4	4
33	Autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, xi-xii	4.6	4
32	Chronic Hepatitis <b>2006</b> , 729-747		4
31	Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis <b>1996</b> , 24, 1068		4
30	Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 2493-2512	4	4

29	Autoimmune liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2000</b> , 16, 262-70	3	3
28	Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 3705-3733	5.6	3
27	Current management strategies for hepatocellular carcinoma. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2013</b> , 59, 143-59	1.6	3
26	Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion. <i>Hepatology</i> , <b>2010</b> , 52, 1177-84	11.2	2
25	Special report: Autoimmune hepatitis. <i>Current Treatment Options in Gastroenterology</i> , <b>1999</b> , 2, 423-436	2.5	2
24	Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	2
23	Review article: targeting the B cell activation system in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 902-922	6.1	2
22	Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, S72-S81.	1.2	1
21	Chapter 11 Immunopathogenesis of Autoimmune Liver Damage. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 121-139	0.3	1
20	Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	1
19	Autoimmune hepatitis: clinical and laboratory diagnosis	153-170	1
18	Current Advances in the Treatment of Autoimmune Hepatitis. <i>Gastroenterology and Hepatology</i> , <b>2006</b> , 2, 107-110	0.7	1
17	Reply:. <i>Hepatology</i> , <b>2010</b> , 52, 1857-1858	11.2	0
16	Letter: high ferritin to haemoglobin ratio is related to early mortality in patients with alcoholic hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1457-1458	6.1	
15	Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 959-960	6.1	
14	Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1104-1105	6.1	
13	Letter: reversibility of hepatic fibrosis and immunosuppression withdrawal in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 794-5	6.1	
12	Letter: guidelines for the management of autoimmune hepatitis - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 115-6	6.1	



- 11 Letter: treatment of autoimmune acute liver failure--beyond consensus guidelines; author's reply. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 1144 6.1
- 10 Arthur Joseph McCullough, Jr., 58th President, AASLD. *Hepatology*, **2008**, 47, 775-6 11.2
- 9 Autoimmune liver disease. *Current Opinion in Gastroenterology*, **2001**, 17, 268-75 3
- 8 Liver blood flow using clearance techniques. *Hepatology*, **1984**, 4, 746 11.2
- 7 Diagnosis and management of chronic active hepatitis B. *Comprehensive Therapy*, **1988**, 14, 46-53
- 6 Therapy of autoimmune diseases - state of the art **2000**, 311-324
- 5 Autoimmune Liver Disease **2004**, 121-125
- 4 Overlap Syndromes of Primary Sclerosing Cholangitis **2017**, 41-57
- 3 Autoimmune Liver Diseases: Autoimmune Hepatitis **2017**, 217-250
- 2 Autoimmune Liver Diseases: Overlap Syndromes **2017**, 307-328
- 1 Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases **2019**, 251-305